This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,339.18 contract is for the delivery of Xtandi 80 mg tablets, a prescription medication used to treat prostate cancer. The delivery order is part of a larger single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA, which allows the agency to issue delivery orders for a wide range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. This contract is not associated with any set-aside designation, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards across multiple medical product categories.
Generated 2/18/25, 1:45 PM